Brief: Neoleukin Therapeutics Inc - Current Best Estimate Of Costs It Will Incur For The Restructuring Plan Total Between $2.5 Million And $3.0 Million

Neurogene

10/03/2023 13:28

March 10 (Reuters) - Neoleukin Therapeutics Inc
 NLTX.O :
    * NEOLEUKIN THERAPEUTICS INC - CURRENT BEST ESTIMATE OF
COSTS IT
WILL INCUR FOR THE RESTRUCTURING PLAN TOTAL BETWEEN $2.5 MILLION
AND $3.0 MILLION
    * NEOLEUKIN THERAPEUTICS INC - APPROXIMATELY $0.3 MILLION OF
THESE
COSTS ARE EXPECTED TO BE NON-CASH EXPENSES
    * NEOLEUKIN THERAPEUTICS INC - MAJORITY OF THESE COSTS ARE
EXPECTED TO BE INCURRED DURING THE FIRST HALF OF 2023

Further company coverage:  NLTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))